Pneumatosis Intestinalis After Panitumumab Chemotherapy for Transverse Colon Cancer：A Case Report

Abstract

Pneumatosis intestinalis（PI）is defined as gas in the bowel wall, and is a condition that can range from benign to fatal. It is sometimes associated with acute mesenteric ischemia, which would necessitate urgent surgical intervention. The pathogenesis of PI is thought to be multifactorial, and the causes include mechanical, bacterial and biochemical factors. Several reports have been published of PI caused by molecular-targeted therapy, including treatment with epidermal growth factor receptor（EGFR）inhibitors, such as panitumumab and cetuximab. Herein, we report a case of PI that developed during treatment with panitumumab in a patient with recurrent transverse colon cancer. We did not undertake surgical exploration, as bowel necrosis and bowel obstruction seemed unlikely. The patient gradually stopped complaining of symptoms, and the PI was no longer detected on CT on the 8th hospital day. PI can be resolved by discontinuation of the culprit drugs, which could help avoid emergency surgery.